title: Anti-osteoporotic activity of puerarin 6"-O-xyloside on ovariectomized mice and its potential mechanism.
abstract: BACKGROUND
  Osteoporosis is one of the most common bone diseases, and radix of Pueraria lobata (Willd.) Ohwi possesses an obvious therapeutical effect on postmenopausal osteoporosis.
  
  
  OBJECTIVE
  This study investigates the anti-osteoporotic activity of the puerarin 6"-O-xyloside (PXY) on ovariectomized mice and its related mechanism.
  
  
  METHODS
  Osteoporotic mice model was established by ovariectomy (OVX). A total of 50 mice were divided into five groups (n = 10): sham, OVX group, PXY treatment groups (20, 40, and 60 mg/kg/d, i.p.). After 12 weeks' treatment, body weights were recorded. Then, mice were sacrificed, and serum samples were collected to determine the blood calcium, blood phosphorus, alkaline phosphatase (ALP), and osteoprotegerin (OPG) concentrations and uterine index was assayed. The thigh-bones of mice were collected to evaluate histopathological changes. In the in vitro experiment, the effect of PXY on osteoblasts' proliferation was evaluated and western blotting was performed to determine expressions of OPG and the receptor activators of NF-κB ligand (RANKL), as well as the ratio of OPG/RANKL.
  
  
  RESULTS
  PXY (40 and 60 mg/kg/d, i.p.) obviously decreased body weights and increased uterine index of OVX (p < 0.05), and improved osteoporotic syndromes of OVX mice; PXY also significantly increased the concentrations of blood calcium, blood phosphorus, ALP, and OPG of OVX mice (p < 0.05); moreover, PXY obviously up-regulated the ratio of OPG/RANKL (p < 0.05).
  
  
  CONCLUSIONS
  Our results demonstrated that the puerarin 6"-O-xyloside possesses significant anti-osteoporotic activity on ovariectomy mice.
authors: a Department of Histology and Embryology .
authors: Hai
authors: H
authors: Li
authors: b Department of Anatomy , and.
authors: Bingpu
authors: B
authors: Chen
authors: c Department of Laboratory Medicine , Youjiang Medical University for Nationalities , Baise , China.
authors: Guangfu
authors: G
authors: Pang
authors: a Department of Histology and Embryology .
authors: Jianhai
authors: J
authors: Chen
authors: a Department of Histology and Embryology .
authors: Jisheng
authors: J
authors: Xie
authors: a Department of Histology and Embryology .
authors: Hailing
authors: H
authors: Huang
mesh_terms: D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D015415:Biomarkers / Q000097:blood; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D016723:Bone Remodeling / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D002118:Calcium / Q000097:blood; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D006027:Glycosides / Q000494:pharmacology*; D006801:Humans; D007529:Isoflavones / Q000494:pharmacology*; D008813:Mice, Inbred ICR; D010006:Osteoblasts / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000209:etiology / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D053244:Osteoprotegerin / Q000097:blood; D010052:Ovariectomy; D010758:Phosphorus / Q000097:blood; D053245:RANK Ligand / Q000378:metabolism; D013997:Time Factors
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D006027:Glycosides; D007529:Isoflavones; D053244:Osteoprotegerin; D053245:RANK Ligand; C506031:Tnfrsf11b protein, mouse; C505689:Tnfsf11 protein, mouse; C000610752:puerarin 6'-O-xyloside; D010758:Phosphorus; D000469:Alkaline Phosphatase; D002118:Calcium
keywords: OPG/RANKL; OVX; osteoblasts; radix of Pueraria lobata (willd.) ohwi